Epigenetic reprogramming of monocytes in patients with coronary atherosclerosis - Trained immunity in atherosclerosis

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 40 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Patients (male/female), aged >18 years, admitted to the acute coronary unit of the CWZ hospital for evaluation of chest pain.
•- No coronary atherosclerosis (TPS<=0): then participation in the control group.
•- Severe atherosclerosis (TPS<=>6): then participation in the patient.

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•- Acute coronary syndrome (ST-segment elevation or depression and elevated plasma troponin levels)
•- Use of statins or thrombocyte aggregation inhibitors (since these drugs have been shown to modulate epigenetic changes in in vitro studies). Of course, these drugs can be given after blood sampling if clinically indicated.
•- Signs or symptoms of a current infection (fever, chills)
•- Auto-immune diseases (such as rheumatoid arthritis)

发起方

niversitair Medisch Centrum Sint Radboud